Polymer Capital Management HK LTD Buys Shares of 500 Eli Lilly and Company (NYSE:LLY)

Polymer Capital Management HK LTD bought a new stake in Eli Lilly and Company (NYSE:LLY) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 500 shares of the company’s stock, valued at approximately $443,000.

Several other institutional investors also recently bought and sold shares of LLY. Lantz Financial LLC lifted its stake in shares of Eli Lilly and Company by 1.3% during the second quarter. Lantz Financial LLC now owns 1,236 shares of the company’s stock worth $1,119,000 after buying an additional 16 shares during the period. BDF Gestion acquired a new stake in shares of Eli Lilly and Company during the second quarter worth $27,339,000. CCM Investment Advisers LLC lifted its stake in shares of Eli Lilly and Company by 0.9% during the second quarter. CCM Investment Advisers LLC now owns 14,742 shares of the company’s stock worth $13,347,000 after buying an additional 137 shares during the period. CHICAGO TRUST Co NA lifted its stake in shares of Eli Lilly and Company by 2.7% during the second quarter. CHICAGO TRUST Co NA now owns 6,389 shares of the company’s stock worth $5,784,000 after buying an additional 166 shares during the period. Finally, Orrstown Financial Services Inc. lifted its stake in shares of Eli Lilly and Company by 3.0% during the second quarter. Orrstown Financial Services Inc. now owns 849 shares of the company’s stock worth $769,000 after buying an additional 25 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Up 2.0 %

Shares of NYSE LLY opened at $829.82 on Thursday. The company has a current ratio of 1.27, a quick ratio of 0.97 and a debt-to-equity ratio of 2.03. The stock has a market cap of $787.76 billion, a PE ratio of 89.71, a P/E/G ratio of 3.03 and a beta of 0.41. The company has a 50-day moving average of $845.38 and a 200 day moving average of $871.07. Eli Lilly and Company has a 12-month low of $561.65 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion during the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.10 earnings per share. As a group, sell-side analysts predict that Eli Lilly and Company will post 13.2 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be issued a $1.30 dividend. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.63%. Eli Lilly and Company’s payout ratio is 56.22%.

Insider Buying and Selling at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. This represents a 14.11 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently commented on LLY. Barclays lowered their price objective on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. Guggenheim boosted their target price on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday, August 16th. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research report on Thursday, October 31st. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Friday, September 13th. Finally, Morgan Stanley restated an “overweight” rating and set a $1,106.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.